Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

Exit

Acquired byTekmira Pharmaceuticals
Price$32.5M
Date3/2008

General Information

Websiteprotivabio.com
CategoryBioTech
Phone206-325-2412
Employees26
Founded2000

Offices

Seattle, USA
1127 41st Avenue East
Seattle, WA, 98112
USA

People

Funding

Tags

Protiva Biotherapeutics

Protiva Biotherapeutics, Inc., a development stage biotechnology company, develops nucleic acid based pharmaceutical products. The company focuses on developing products to fight various human diseases, such as cancer, influenza, Ebola, inflammatory diseases, and chronic viral infections. Its products include Pro 1, a tumor cell growth inhibitor, which kills tumor cells and inhibits tumor growth; Pro-101, an siRNA product that acts to inhibit the production of a protein involved in tumor growth; Pro-B, which acts to inhibit the expression of a protein, apolipoprotein B; Pro-EBOV and Pro-MARV that act to inhibit the replication of the Ebola and Marburg viruses; and Stable Nucleic-Acid Lipid Particle technology, an encapsulation and delivery system for nucleic acid payloads, such as short interfering RNA (siRNA), to target cells. The company also develops Hepatitis siRNA products for the treatment of hepatitis B and C. Protiva Biotherapeutics, Inc. has a research and development facility in Vancouver, Canada. The company was founded in 2000 and is based in Seattle, Washington. As of May 30, 2008, Protiva Biotherapeutics, Inc. operates as a subsidiary of Tekmira Pharmaceuticals Corp.

Recent Milestones

Videos

Screenshots

Sources

  1. Cap Funding Report [edit]
  2. EDGAR [edit]
  3. EDGAR [edit]
Edit This Page
Last Edited 4/27/10

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize ยป

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy